Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

Abstract Context Immune-checkpoint inhibitors (ICIs) are a mainstay treatment of metastatic
renal cell carcinoma (mRCC). As not all patients benefit from ICIs, a biomarker-driven …

Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC)
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …

Purpose Management of metastatic renal cell cancer (mRCC) has undergone a paradigm
shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct …

Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of
metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are …

Abstract Introduction Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for
metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor …

Simple Summary Clinicians often erroneously discount prognostic information as unlikely to
change patient management. This is fueled by the mistaken belief that only “predictive” …

Renal cell carcinoma (RCC) is a most common malignant tumor in the genitourinary system.
Studies have shown that Lycorine has promising anticancer activities with minor side effects …

Background Immuno-oncology (IO) therapies have changed the treatment standards of
metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy …

Purpose To perform a systematic review and meta-analysis of the Prognostic Nutritional
Index (PNI) as a prognostic factor for renal cell carcinoma (RCC). Materials and methods …